International Stem Cell Corp is primarily active in the field of regenerative medicine, focusing on developing and commercializing cell-based therapeutics and biomedical products. With a strong emphasis on stem cell research, the company leverages its proprietary technologies to explore potential applications in various industries such as pharmaceuticals, cosmetics, and research tools. By harnessing the therapeutic potential of stem cells, International Stem Cell Corp aims to revolutionize and improve treatments for a wide range of medical conditions.

The main competitors of International Stem Cell Corp in the market are [competitor names].

International Stem Cell Corp (ISCO) is a renowned biotechnology company with a rich and influential history. Founded in 2001, ISCO specializes in the development and commercialization of novel stem cell-based therapies and biomedical products. With a global presence, the company has made significant breakthroughs in the field of regenerative medicine. ISCO is committed to revolutionizing healthcare by utilizing its proprietary technologies, such as parthenogenesis, to generate pluripotent stem cells. These cells have immense potential for various applications, including treating diseases and disorders. Over the years, International Stem Cell Corp has garnered a strong reputation and remains dedicated to advancing the frontiers of stem cell research, ultimately aiming to improve patients' lives worldwide.

International Stem Cell Corp has achieved several significant milestones in its journey. These include the successful development and commercialization of breakthrough technologies in the field of regenerative medicine. The company has made notable advancements in the use of human parthenogenetic stem cells, producing a potentially unlimited source of cells for research and therapeutic purposes. International Stem Cell Corp has also successfully transformed these cells into various specialized cell types, opening doors to numerous therapeutic applications. With its innovative research and development initiatives, the company continues to pave the way for the advancement of regenerative medicine and holds promising potential for addressing unmet medical needs.

International Stem Cell Corp is primarily present in several countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered and operates its main research and development activities. Additionally, International Stem Cell Corp has a strong presence in major international markets such as Australia, Canada, and the United Kingdom. Through strategic partnerships and collaborations, the company has expanded its reach and operations to other regions, including Europe, Asia, and South America. International Stem Cell Corp's global footprint allows it to leverage diverse markets and access various resources to fulfill its mission in advancing innovative stem cell technologies and therapies.

International Stem Cell Corp represents a strong commitment to advancing regenerative medicine and developing novel therapies using stem cells. The company focuses on harnessing the potential of human parthenogenetic stem cells (hpSCs) to address unmet medical needs. With a dedication to scientific innovation and ethical practices, International Stem Cell Corp aims to provide safe and effective solutions for patients worldwide. Emphasizing rigorous research and development, the company strives to improve the quality of life through the application of cutting-edge stem cell technologies. Their corporate philosophy revolves around delivering groundbreaking treatments while maintaining transparency, integrity, and patient-centricity.

Converted at the current exchange rate, the International Stem Cell share trades at 0,22 EUR (0,25 USD).

The International Stem Cell Corp (ISCO) is a biotechnology company specializing in the research and development of stem cell therapies. The company operates in multiple divisions and offers a variety of products and services. ISCO has its own technology platform that allows for the extraction and cultivation of stem cells from human tissue. The technology allows for the production of stem cells without any alterations, making them suitable for medical use. One of the company's divisions focuses on the development of stem cell therapies. ISCO is working on therapies for a range of diseases and injuries. The company has already made successful progress in developing therapy approaches for Type 1 diabetes and aims to achieve breakthroughs in other medications. Another business area for ISCO is the manufacturing of cell products and services. The company offers both cell products and cell manufacturing services, enabling other companies to produce their own products based on stem cells. ISCO has its own production facilities in California and Singapore. Additionally, ISCO operates a veterinary medicine division, which focuses on developing stem cell therapies for pets. The company researches therapies for various animal diseases and develops cell-based products for animal health. Overall, ISCO takes a holistic approach to the development of stem cell therapies and cell products. The company places equal emphasis on scientific research and product development for consumer use. ISCO's business model has been highly successful, leading to consistent growth in recent years. Since its founding in 2001, the company has successfully completed multiple rounds of financing and plans to launch more products and therapies in the future. Through a combination of extensive research and development and a successful product range, ISCO has established itself as a leading company in the field of stem cell therapies. With a global presence and a strong position in veterinary medicine, the company will continue to play an important role in researching new therapeutic possibilities.

odotettu liikevaihto International Stem Cell on 7,32 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto International Stem Cell on −5,76 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

International Stem Cell:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,02. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan International Stem Cell-osakkeen arvostusta.

International Stem Cell:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,02. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii International Stem Cell-osakkeen arvostuskennuslukuna.

International Stem Cell:n Eulpool-laatuscore on 2/10.

International Stem Cell:n ISIN on US4603782016. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

International Stem Cell:n ticker on ISCO. Tämä pörssinoteeraus käytetään International Stem Cell-osakkeiden kauppaan pörssissä.

International Stem Cell maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

International Stem Cell kuuluu sektoriin 'Terveydenhuolto'.

International Stem Cell:n osingot jaetaan valuutassa USD.